INTRODUCTION
Although cholic acid,' chenodeoxycholic acid, and deoxycholic acid are the predominent bile acids in human bile (1) , small amounts of other bile acids including ursodeoxycholic acid are frequently detected (2) . This bile acid is the 713-epimer of chenodeoxycholic acid ( Fig. 1 ) and under normal conditions represents less than 1% of the total biliary bile acids. Little is known about the metabolism and biosynthesis of this 7P-hydroxy bile acid, although several reports have indicated that chenodeoxycholic acid is a precursor (3) (4) (5) .
Recently, large quantities of the primary bile acid, chenodeoxycholic acid, have been administered to patients with gallstones (6, 7) and the rare inherited lipidosis, cerebrotendinous xanthomatosis (CTX)2 (8) . In the patients with gallstones progressive diminution in size and eventual dissolution of the stones have been ' The following systematic names are given to sterols and bile acids referred to by trivial names: cholesterol, cholest-5-en 3,8-ol; 7a-hydroxy-cholesterol, cholest-5-ene-3j3, 7a-diol; cholic acid 3a, 7a, 12a-trihydroxy 5,6-cholanoic acid; chenodeoxycholic acid, 3a, 7a-dihydroxy-5,8-cholanoic acid; ursodeoxycholic acid, 3a, 7,8-dihydroxy-5,6-cholanoic acid; deoxycholic acid, 3a, 12a-dihydroxy-5fi-cholanoic acid; lithocholic acid, 3a-hydroxy-5p6-cholanoic acid; 7- ketolithocholic acid, 3a-hydroxy-7-keto-5,8-cholanoic acid; allocholic acid, 3a, 7a, 12a-trihydroxy-5a-cholanoic acid. ' Abbreviations used in this paper: CTX, cerebrotendinous xanthomatosis; GLC, gas-liquid chromatography; RRT, relative retention time; SGOT described, while in the CTX subjects, marked reduction in cholesterol and cholestanol synthesis rates were noted. During the course of these studies, striking alterations in biliary bile acid composition were observed Which included the virtual disappearance of cholic acid from the bile (6) . This report describes the changes in biliary bile acid composition in seven individuals treated with chenodeoxycholic acid for 4 months. In addition to the effect on cholic acid metabolism, increased amounts of a new bile acid were detected. This bile acid was identified as ursodeoxycholic acid, and was derived from chenodeoxycholic acid probably via a keto-bile acid intermediate.
METHODS
Clinical. Studies were conducted in seven patients hospitalized at the Manhattan Veterans Administration Hospital. Three subjects (E. D. E., E. D. S., and J. C.) suffered from the rare inherited lipidosis, cerebrotendinous xanthomatosis. Complete clinical and biochemical descriptions of these patients have appeared elsewhere (9) (10) (11) . Four subjects (T. S., R. P., I. R., and K. S.) had radiolucent gallstones demonstrated by oral cholecystography. No patient was acutely ill during the course of these studies, and clinical laboratory tests including a complete blood count, urinalysis, fasting blood sugar, blood urea nitrogen, serum bilirubin, serum transaminase (SGOT), serum alkaline phosphatase, and plasma prothrombin time were normal at the beginning of the study and did not change during chenodeoxycholic acid treatment. Liver biopsies were performed after 4 months of bile acid treatment and were interpreted as normal. The patients ate regular diets that were devoid of foods containing large amounts of cholesterol. Caloric intakes were adjusted to maintain constant weight during these studies.
Bile acid analysis. The percent composition of individual bile acids in specimens of duodenal bile was determined according to the method described for fecal bile acids by Grundy, Ahrens, and Miettinen (12) . Samples of bile were aspirated from the duodenum via a Rehfus tube (Davol, Inc., Providence, R. I) that was positioned under fluoroscopic guidance. Cholecystokinin (obtained from the late Professor Erik Jorpes, Karolinska Institute, Stockholm, Sweden) was injected intravenously to facilitate gallbladder bile flow.
2 ml (2.00) of bile were refluxed for 1 h with 20 ml of N ethanolic NaOH. After the neutral sterols were extracted with hexane, the ethanol was evaporated from the mixture and 15 ml of 2 N NaOH were added. Further saponification for 3 h at 15 psi was carried out to deconjugate the bile acids. After acidification to pH 2 with concentrated HCl and the addition of 20 ml of methanol, the free bile acids were extracted with 3-40-ml portions of chloroform. The solvent was evaporated and the bile acid methyl esters were formed by the addition of 5% HCl in dry methanol (w/w). The methyl esters of the trihydroxy-, dihydroxy-, and monohydroxycholanoic acids were isolated as a group by TLC on 20 X 20 cm glass plates coated with 0.5 mm thick layers of Silica Gel H prerun in methanol and activated at 110'C for 1 h before use. The plates were first developed with benzene to separate the fatty acids and then with trimethylpentane: isopropanol: acetic acid, 75: 25:1; solvent migration was stopped beneath the fatty acid band. The total bile acid mixture was eluted with acetone in a vacuum aspirator (13) Table I ).
The solvent was evaporated and 5.00 ml of ethyl acetate containing 350 ,ug of 5a-cholestane as an internal standard was added. 4 (4.00) ml were taken for radioactivity assay, and the remainder was utilized for quantitation of bile acids by GLC. Mass measurements were obtained on the TMS-ether bile acid methyl ester derivatives as described above. The specific activities of methyl chenodeoxycholate and methyl ursodeoxycholate were computed from the total radioactivity divided 'by mass. Mass spectroscopy. The identity of the individual acids was established by GLC-mass spectrometry utilizing a Varian Model-111 gas chromatograph-mass spectrometer (Varian MAT, Palo Alto, Calif.). Between 5 and 10 lug of the total bile acid mixture (TMS-ether methyl ester derivatives) were injected onto a 6-foot X A" helical glass column packed with 1% Hi Eff 8BP on 100/120 mesh Gas Chrom Q maintained at 2500 C. The temperature of the inlet was 10°-20°above column temperature while the molecular separator was operated at 3000C.
The same mass of a known reference compound was injected separately, and both the retention times and the mass spectra of the individual bile acids were compared.
Radioactive assay. The purified bile acid methyl esters (isolated by TLC) were dissolved in 18 ml of toluene phosphor (4.2% Liquiflor, New England Nuclear Corp., Boston, Mass. Mass spectra of the TMS-ether derivatives of known methyl ursodeoxycholate, known methyl chenodeoxycholate, and methyl ester of peak V (Fig. 2 B) . cholic acid (36% and 37%, respectively), and substantial quantities of the secondary bile acid deoxycholic acid. Trace amounts of the secondary bile acid lithocholic acid also were found. After 4 months of treatment, the proportion of chenodeoxycholic acid increased to over 80% in six of seven subjects, while cholic acid declined to less than 10% of the total bile acids. In the gallstone subjects, the secondary bile acid, deoxycholic acid, disappeared from the bile, while in the CTX subjects both allocholic acids and the polar steroids were eliminated. However, all subjects showed increasedamounts (3-37% of the total bile acids) of a new bile acid that was conclusively identified (see below) as ursodeoxycholic acid. In subject T. S., a small amount (2%) of ursodeoxycholic acid was detected before chenodeoxycholic acid therapy, but the proportion increased to 37% of the total biliary bile acids after treatment (Figs. 2 A and B) .
It is noteworthy that in five of six subjects lithocholic acid the 7a-dehydroxylated bacterial metabolite of chenodeoxycholic acid did not increase in the bile of the subjects despite the large intake, of chenodeoxycholic acid. Perhaps lithocholic acid was not formed or was not absorbed from the colon because of the diarrhea associated with feeding chenodeoxycholic acid (6) . Another explanation for the absence of lithocholic acid from the bile is the possibility of sulfate formation. Lithocholic acid sulfate is quite polar and unfortunately, if present, would not be detected by our analytical procedure.
Identification of ursodeoxycholic acid. As illustrated in Fig. 2 B, the TMS-ether derivative of methyl ursodeoxycholate and methyl chenodeoxycholate were easily distinguished by GLC. Furthermore, the two bile acid methyl esters could be separated by TLC (see Methods). When samples of known methyl ursodeoxycholate were cochromatographed with the biosynthetic product (peak V, Fig. 2 B) , identical Rr and RRT values were observed.
Positive identification of peak V, Fig. 2 B was established by GLC-mass spectrometry. Fig. 3 illustrates the mass spectra for the TMS-ether derivatives of known methyl chenodeoxycholate, known methyl ursodeoxycholate, and peak V. Although methyl chenodeoxycholate and methyl ursodeoxycholate share the same chemical formula, striking differences were observed in their fragmentation patterns. For the TMS ether of methyl chenodeoxycholate, no molecular ion (M) was detected at m/e 550, and the largest fragment was at m/e, 370 which corresponds to M -2 X {OSi(CH3)sH} or 550-2 X 90. In contrast the mass spectrum of the TMS ether derivative of known methyl ursodeoxycholate The mass spectrum of the TMS ether derivative of the methyl ester of peak V (Fig. 2 B) is identical line for line with the fragmentation pattern of the TMS ether of authentic methyl ursodeoxycholate. Thus, the correspondence obtained by three independent methods (TLC, GLC, and mass spectrometry) conclusively proves that ursodeoxycholic acid was present in the bile of our subjects.
The effect of chenodeoxycholic acid on the sequential changes in biliary bile acid composition. Fig. 4 illustrates the daily changes in bile acid composition that were produced by the administration of chenodeoxycholic acid to patient J. C. (CTX). After 1 day of therapy, chenodeoxycholic acid increased to 40% of the biliary bile acids, then rose to over 80% of the total bile acids by the third day. In contrast, the proportion of cholic acid declined to less than 10% of the total bile acids by day 5. Ursodeoxycholic acid did not appear in the bile until the fifth day and then increased to 7% of the total bile acids by day 7 -ketolithocholic Acid-3H FIGURE 7 The specific activity decay curves of ursodeoxycholic acid and chenodeoxycholic acid after the administration of [8H]7-ketolithocholic acid. After the administration of a tracer dose of the 7-keto bile acid, radioactivity was detected in both the chenodeoxycholic acid and ursodeoxycholic acid fractions. ministration of ['H]chenodeoxycholic acid to three subjects with CTX who were receiving chenodeoxycholic acid, the specific activities of ursodeoxycholic acid and chenodeoxycholic acid were measured for the next 3-4 days. The results are presented in Fig. 5 . As expected, the specific activity of chenodeoxycholic acid decayed linearly in all three subjects. In contrast, the specific activity of ursodeoxycholic acid in E. D. S. on day 1 was i lower than that of chenodeoxycholic acid, and then rose to exceed the specific activity of chenodeoxycholic acid. In J. C., the specific activity of ursodeoxycholic acid was greater than chenodeoxycholic acid by the second day and then decayed in a parallel manner. In E. D. E., the specific actiivty of ursodeoxycholic acid rose and became greater than chenodeoxycholic acid on the third day. The demonstration of 'H radioactivity in the ursodeoxycholic acid fractions of these subjects plus the appearance of the specific activity-time curves suggest that ursodeoxycholic acid was derived from cheinodeoxycholic acid. Fig. 7 . 1 day after oral pulse-labeling, tritium radioactivity was detected in both dihydroxy bile acids and indicated that 7-ketolithocholic acid was converted into chenodeoxycholic acid and ursodeoxycholic acid. Since the specific activities of both bile acids were almost identical on day 1, the 7-keto bile acid probably was reduced equally into its respective 7a-and 7P-hydroxy Step I C____ HO %OH e 7a, 12a -dihydroxycholest -4-en-3-one
Step IR Chenodeoxycholic Acid Cholic Acid FIGURE 8 The bile acid synthetic pathway. The two major rate-determining reactions are indicated:
Step I controls the formations of 7a-hydroxycholesterol and step II controls the 12a-hydroxylation of 7a-hydroxycholest-4-en-3-one.
derivatives. DISCUSSION The results of this investigation demonstrate the striking changes in bile acid metabolism produced by the administration of chenodeoxycholic acid to gallstone and CTX subjects. After 4 months of therapy, cholic acid was virtually eliminated from the bile and was replaced by chenodeoxycholic acid. In the gallstone subjects, deoxycholic acid was no longer detected. This change probably reflects the absence of cholic acid from the enterohepatic circulation and, as a consequence, a decreased availability of this bile acid as substrate for bacterial 7a-dehydroxylation. In the CTX subjects, the small amounts of allocholic acid and polar steriods were also reduced below the limits of detectability. These differences apparently result from the feedback inhibition of chenodeoxycholic acid on cholic acid production. The major rate-determining reactions governing bile acid synthsis are summarized in Fig. 8 . Both cholic acid and chenodeoxycholic acid are derived from a common intermediate, 7a-hydroxycholest-4-en-3-one, which is formed from 7a-hydroxycholesterol (16) . The ketosteroid is then 12a-hydroxylated to form 7a, 12a-dihydroxycholest-4-en-3-one the first totally committed precursor of cholic acid biosynthesis. Therefore, cholic acid synthesis would be suppressed by either the inhibition of the 12a-hydroxylation reaction (step II) or the inhibition of the 7a-hydroxylation of cholesterol (step I). In the former case, only cholic acid production would be affected, while in the latter instance both cholic acid and chenodeoxycholic acid formation would be diminished. Samuelsson (15) who showed that radioactivity 7-ketolithocholic acid was converted into both ursodeoxycholic and 3a, 6A, 7P-trihydroxy-5#-cholanoic acid (#-muricholic acid) in rats. Since the enterohepatic circulation in these animals was interrupted, the reduction of the 7-keto group was presumably a hepatic process rather than carried out by bacteria in the intestine. In the present study, 7-ketolithocholic acid was not detected in bile and feces of the chenodeoxycholic acid-treated patients. However, Haslewood, Murphy, and Richardson have isolated a strain of E. coli from the intestinal contents of a patient with bacterial overgrowth that has specific 7a-hydroxy dehydrogenase activity (18). This finding suggests that bacteria are capable of producing 7-ketolithocholic acid from chenodeoxycholic acid. Therefore, although a tracer dose of radioactive 7-ketolithocholic acid was converted into ursodeoxycholic acid, neither its formation nor its role as a precursor of ursodeoxycholic acid have been definitely established. An alternative explanation for the formation of ursodeoxycholic acid is that the 7a-hydroxy group of chenodeoxycholic acid could be directly epimerized in the liver. This mechanism might control the hepatic content of chenodeoxycholic acid and may be analogous to the formation of a-and P-muricholic acids from chenodeoxycholic acid in the rat (4, 17, 19) . Furthermore, since 7-ketolithocholic acid was also reduced to chenodeoxycholic acid, it is possible that ursodeoxycholic acid was derived indirectly from 7-ketolithocholic acid via chenodeoxycholic acid. Also we have not ruled out the possibility that ursodeoxycholic acid was produced by bacteria in the intestine.
A major advance of this study was the conclusive identification of ursodeoxycholic acid by the combination of TLC, GLC, and mass spectrometry. These steps greatly minimized the possibility that the radioactivity found in the ursodeoxycholic acid fraction represented contamination with chenodeoxycholic acid.
A (21) . Although there is scant documentation of the presence of ursodeoxycholic acid in human bile, the increasing use of chenodeoxycholic acid and demonstration of its convertability into ursodeoxycholic acid mandates a fuller investigation of the the metabolism of these bile acids in man.
